Tranylcypromine is a monoamine oxidase inhibitor used to treat major depressive disorder. A propylamine formed from the cyclization of the side chain of amphetamine.
- Mechanism
- Curator reviewed
Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.
- Primary indication
- For the treatment of major depressive episode without melancholia.Curator reviewed · 1 structured indication
- Formula / weight
- C9H11N · 133.194 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1989
- Also known as
- dl-tranylcypromine · Racemic Tranylcypromine · Transamine
- Code names
- SKF 385 · SKF Trans-385
- Brand names
Resolves to
AELCINSCMGFISI-UHFFFAOYSA-NSMILESNC1CC1C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Tranylcypromine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account